HONG KONG, July 23, 2018 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current People's Republic of China government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood CorporationInvestor Relations DepartmentTel: (+852) 3605-8180Email: firstname.lastname@example.org
ICR, Inc.Mr. William ZimaTel: (+86) 10-6583-7511U.S. Tel: (646) 405-5185Email: William.email@example.com
View original content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-files-its-annual-report-on-form-20-f-300684669.html
SOURCE Global Cord Blood Corporation
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All